Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.
about
Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten CarrierFactors contributing to the immunogenicity of meningococcal conjugate vaccinesHuman immunity and the design of multi-component, single target vaccines.Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in micePertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.A study of physico-chemical interactions between Haemophilus influenzae type b and meningococcus group C conjugate vaccinesImmunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infantsPatterns of binding of aluminum-containing adjuvants to Haemophilus influenzae type b and meningococcal group C conjugate vaccines and componentsA Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A.Combination conjugate vaccines.Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates.Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity.10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines.Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.The history of pneumococcal conjugate vaccine development: dose selection.Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage.Tetanus-diphtheria-pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (coadministered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial⋆.Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
P2860
Q28542642-B0FA2716-7E72-4C28-B588-1F583F5A2D66Q28828544-8F5BB98A-9CF1-4A8F-8A79-B79C466BFB15Q33297012-DB6F76F9-76F6-4081-B7A5-F45DB3E17214Q33557154-9241A503-2497-4781-98D9-A0CDF5596A6EQ33594345-2FF1534C-F088-402D-A6EB-63E2237B474AQ33899407-6090AC18-8004-4004-9658-EC743262579FQ34170021-1437A601-18FF-4920-977D-5B984C4C3703Q34444503-54FB4CCB-7F0E-4B58-9C91-DDDFC69BEA85Q34780775-5CC62B7A-0930-4EBD-AD9A-355FD85C5D64Q34981631-AC4A9C97-DB1A-4CF3-B5AF-5FAC8B2FE96FQ36090625-425683BD-C721-4141-83C2-FB1A602E331CQ36409520-32017F44-ED96-4F8A-B112-854C1F2A04CBQ36446881-A39AFB74-4EB4-4E7E-BB98-A5E82318758BQ36980383-61416BFC-EE01-4117-A764-1765A165AC75Q37077660-5966C6B3-76C5-448D-B537-F936F41A0C96Q37325678-12014BF2-DE23-4FA5-9898-88BF8C5DE5E3Q37621061-1C0D66BB-45F4-4DF2-8112-353EF3CDF52BQ37622887-8178585B-31F6-4AF4-AB17-59B18B200F55Q37857246-028F64BD-1A00-4467-9BB7-732D85988293Q37951530-9703D4DE-29ED-415D-B0FD-9285E73656E6Q38160248-240EE246-F96A-4DF7-B416-513EB1CBBA22Q39344425-5D4D06C7-AEE5-4F65-98C2-19368D504A04Q40265484-E46C3873-3AA6-4E11-AA1A-DDEC1A19B994Q41911560-16A45478-0E2C-4608-A13B-96B01A21604DQ47154849-4F524DA8-D943-415D-B8DF-F3FDFD1C99C2Q54416744-620B3B0B-3693-43FF-8229-241D277FBB36
P2860
Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reduction of antibody response ...... cellular pertussis components.
@en
Reduction of antibody response ...... cellular pertussis components.
@nl
type
label
Reduction of antibody response ...... cellular pertussis components.
@en
Reduction of antibody response ...... cellular pertussis components.
@nl
prefLabel
Reduction of antibody response ...... cellular pertussis components.
@en
Reduction of antibody response ...... cellular pertussis components.
@nl
P2093
P2860
P1476
Reduction of antibody response ...... cellular pertussis components.
@en
P2093
James R Maleckar
Juhani Eskola
Mansour Yaïch
P2860
P304
P356
10.1128/IAI.72.9.5383-5391.2004
P407
P577
2004-09-01T00:00:00Z